Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam in pediatric absence epilepsy
NCT05109234Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), sponsored by UCB. Primary endpoints: Treatment Emergent Adverse Events at 16.32 months and Treatment Emergent Adverse Events Leading to Discontinuation of Study Treatment at 16.32 months. Started Mar 2022; status: completed.
02
Drugs
brivaracetam
03
Conditions
childhood absence epilepsy (CAE)juvenile absence epilepsy (JAE)
Beyond the preview
Go deeper on NCT05109234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109234.